ELISA News and Research

RSS

Experimental Chinese SARS-CoV-2 vaccine appears safe in early trials

A new study published on the preprint server medRxiv in October 2020 reports the findings of a phase I trial of an inactivated SARS-CoV-2 vaccine, demonstrating that it can elicit a potent immune response without significant adverse reactions.

7 Oct 2020

Dried blood spot samples accurately detect anti-SARS-CoV-2 S glycoprotein antibodies

Using dried blood spot samples (DBS) is an accurate alternative to venous blood in detecting SARS-CoV-2 antibody tests, a new study by immunology experts at the University of Birmingham has found.

6 Oct 2020

Research indicates increased breast cancer mortality in African American and Black survivors

Although breast cancer does not discriminate between race or gender, research suggests that there is increased breast cancer mortality and poorer health-related quality of life in female African American and Black survivors of the disease.

6 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

As we improve our understanding of immune responses and correlates of protection against the severe acute respiratory syndrome coronavirus (SARS-CoV-2), two UK researchers emphasize that we will probably utilize different assays to tackle specific questions. Their commentary is published in the prestigious journal Lancet Infectious Diseases.

27 Sep 2020

Large mother-child paired study promises more answers on COVID-19 in pregnancy

A new paper published in the preprint server medRxiv* in August 2020 reports the design and preliminary findings of an ongoing study on pregnant mothers and their children born during the pandemic.

20 Sep 2020

Self-assembling nanoparticles as a way towards next-generation COVID-19 vaccines

In a promising study by US researchers, the receptor-binding domain (RBD) and stabilized spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were displayed on nanoparticles as vaccine antigens and elicited potent immune responses.

16 Sep 2020

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Pandemics caused by novel infectious agents like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika, or Ebola virus seriously impact human health and lives while also overwhelming health care systems all over the world. Early detection and diagnosis allow isolation of the infected patients and contact tracing, which can mitigate the spread of the virus and save lives, especially when a significant number of the patients are asymptomatic.

14 Sep 2020

RUDN geneticist finds a bifidobacterial protein that can reduce inflammation in COVID-19

A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in COVID-19 patients.

14 Sep 2020

Researchers develop highly scalable, accurate antibody test for COVID-19

An antibody test for the virus that causes COVID-19, developed by researchers at The University of Texas at Austin in collaboration with Houston Methodist and other institutions, is more accurate and can handle a much larger number of donor samples at lower overall cost than standard antibody tests currently in use.

12 Sep 2020

New study brings researchers closer to a universal COVID-19 antibody test

A new study released by Houston Methodist takes researchers a significant step closer to developing a uniform, universal COVID-19 antibody test.

11 Sep 2020

Researchers explore IgA response to SARS-CoV-2

A new study published on the preprint server bioRxiv* and conducted by researchers from The Rockefeller University in New York examined the role of IgA antibodies in preventing SARS-CoV-2 infection. In this study, the team analyzed the IgA response to SARS-CoV-2 infection in 149 individuals.

10 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing.

From Gyros Protein Technologies AB 3 Sep 2020

Antibody responses in recovered COVID-19 individuals from India

India has been hit hard by COVID-19, with at least 66,000 deaths and almost 4 million cases. The need to understand the infection, including the various antibody isotypes, and whether neutralizing antibodies and memory B cells are being produced, has driven much research into the way immunity is developing in Indian patients.

3 Sep 2020

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.

25 Aug 2020